Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06915012 · ClinicalTrials.gov registry record · NA
Impact of Biophoton Therapy on Chronic Severe Arthritis Pain
A NA study of Arthritis, sponsored by First Institute of All Medicines.
- Recruiting
- Registry status
- NA
- Development phase
- 102
- Enrollment target
- 1
- Study location
NCT06915012: Recruiting NA study of Arthritis, sponsored by First Institute of All Medicines.
NCT06915012 is a NA study of Arthritis that is actively recruiting participants, run by First Institute of All Medicines. The registered enrollment target is 102 participants, below the 4,508-participant average among 48 other Arthritis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06915012, a NA study of Arthritis, is actively recruiting participants, sponsored by First Institute of All Medicines.
- RECRUITING
- Registry status
- NA
- Development phase
- 102 participants
- Enrollment target
- 1
- Study location
Study Summary
Study Objective The purpose of this clinical study is to evaluate if biophoton therapy, delivered by Tesla BioHealing® Biophoton Generators (Biophotonizer), can alleviate chronic severe pain. Study Design This is a randomized, double-blinded, placebo-controlled intervention clinical study to assess the effectiveness of biophoton therapy in managing chronic severe pain. Approximately 102 patients with chronic severe arthritis pain will participate in the study. Study Randomization The biostatistician will prepare a randomization schedule including a series of subject numbers. A subject number will be randomly assigned to each study participant, which will assign them to either the control group or the treatment group. Other than the Informed Consent Form (ICF), all study information will be recorded by using the subject number. The Principal Investigator, study physicians, study nurse, data-entry specialists, and biostatisticians, as well as the participants (and caregivers), will be blinded about who received which product during the first two weeks of study participation. Study Enrollment Each potentially qualified patient will review the Informed Consent Form online (e-ICF) and Enrollment Criteria online (e-Criteria) first, then discuss the e-ICF and e-Criteria with the study team medical professional via telephone during the scheduled time. Each qualified patient will sign the e-ICF and send it to the Study Coordinator. The Study Coordinator will assign the qualified patient a randomized subject number, then the patient will become a study participant. Study Procedure We expect that the participant will stay in this clinical treatment for 12 weeks, or 12 weeks if the participants are randomly placed in a placebo group. The 12 weeks of participation are double-blinded to record the placebo effects, as each set of the study device is labelled with a unique code for use by only one participant. The change of the placebo device to the treatment device will be pe
Primary Outcome
VAS score to measure reduction in pain levels
Conditions Studied
Interventions
- DEVICE Tesla BioHealing(R) Biophoton Generators
Study Locations (1)
Pennsylvania
- Tesla BioHealing Medical Center in Butler-PA - Butler
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2025-03-28 |
| Est. Completion | 2026-03-31 |
| Phase | NA |
What NCT06915012 shows while recruiting
NCT06915012 is an interventional study that assigns participants to a tested intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap, below the 4,508-participant average among 48 other Arthritis trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Arthritis appearing as the primary indexed condition, and to 1 intervention - of which Tesla BioHealing(R) Biophoton Generators is the first listed.
NCT06915012 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06915012 about?
NCT06915012 is a clinical study titled "Impact of Biophoton Therapy on Chronic Severe Arthritis Pain". Study Objective The purpose of this clinical study is to evaluate if biophoton therapy, delivered by Tesla BioHealing® Biophoton Generators (Biophotonizer), can alleviate chronic severe pain. Study Design This is a randomized, double-blinded, placebo-controlled intervention clinical study to assess...
What is the current status of trial NCT06915012?
This trial is currently recruiting. It is a NA study. The enrollment target is 102 participants. The study started on 2025-03-28. Estimated completion is 2026-03-31.
What conditions does trial NCT06915012 study?
This clinical trial studies the following conditions: Arthritis.
What interventions are being tested in trial NCT06915012?
The interventions under investigation include: Tesla BioHealing(R) Biophoton Generators (DEVICE).
Who is sponsoring clinical trial NCT06915012?
This trial is sponsored by First Institute of All Medicines, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06915012 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06915012's enrollment target sits among peer trials
102 27th of 48 higher than 21 of 48 other Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Expanding Exercise Programming for Veterans Through Telehealth
RECRUITING · NA
-
Dose Response of Exercise for Arthritis Management
RECRUITING · NA
-
Aptis PRUJ Prosthesis for the Treatment of Patients With Proximal Radial Ulna Joint Disorders.
RECRUITING · NA
-
Geniculate Artery Embolization for Osteoarthritis
RECRUITING · NA
-
Comparing Functional Outcomes in Individuals Using Micro-processor Controlled Orthosis Versus Stance Control Orthosis
ACTIVE NOT RECRUITING · NA
-
Impact of Different Exercise Programs on Knee OA
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03704662 · 102 participants · NA
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
- NCT04174742 · 102 participants
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
- NCT04275362 · 102 participants
Gait Analysis of a Lateral-Pivot Design Total Knee Replacement
- NCT04541082 · 102 participants · Phase 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI